Acute Respiratory Distress Network (ARDSNet) Study 04 Assessment of Low tidal Volume and elevated End-expiratory volume to Obviate Lung Injury (ALVEOLI) - Catalog

Name

Acute Respiratory Distress Network (ARDSNet) Study 04 Assessment of Low tidal Volume and elevated End-expiratory volume to Obviate Lung Injury (ALVEOLI)

Accession Number

HLB00500606a

Acronym

ARDSNet-ALVEOLI

Related studies

BSI Study IDs

AR4

Is public use dataset

False

Keywords

Has Study Datasets

True

Has Specimens

True

Specimen ID Type

Coded

Study Website

http://www.ardsnet.org/

The Framingham Heart Study Group requires that the requestor must obtain full or expedited IRB/Ethics Committee review and approval to obtain these data. Waivers or a determination that the research is exempt from ethical regulations do not suffice.

False

Study type

Clinical Trial

Collection Type

Open BioLINCC Study

Cohort type

Both

Interventions

Procedure: Low Tidal Volume VentilationProcedure: Positive End-Expiratory PressureDrug: LysofyllineDrug: MethylprednisoloneDrug: KetoconazoleProcedure: Fluid ManagementProcedure: Pulmonary Artery Catheter

Study Open Date (Data)

2009-10-01

Study Open Date (Specimens)

2010-04-09

Date materials available

2008-10-13

Last updated

2006-08-24

Study period

1999-2002

Study Contacts
NHLBI Division

DLD

Classification

Lung

HIV study classification

non-HIV

COVID study classification

non-COVID

Pre-Website # of Specimens Shipped

3874

# of Returned Specimens

0

Conditions

ALI
ARDS
Acute Lung Injury
Lung Diseases
Respiratory Distress Syndrome, Adult

Objectives

The ARDS Network is a consortium of clinical centers and a coordinating center to design and test novel therapies for the treatment of Acute Lung Injury (ALI) and Acute Respiratory Distress Syndrome (ARDS). The ARDS Network 01/03 trials included an investigation of the efficacy and safety of Ketoconazole and Respiratory Management in the treatment of ALI and ARDS (KARMA). The Ketoconazole arm of the KARMA study was later stopped due to an inability to show efficacy. Patients continued to be randomized to the respiratory management arms of the study (ARMA), which compared two ventilator strategies: a tidal volume of 6 mL/kg versus 12 mL/kg. The LARMA phase of the study investigated the efficacy of Lisofylline and Respiratory Management. The objective of the ALVEOLI study was to compare clinical outcomes of patients with ALI and ARDS treated with a higher end-expiratory lung volume/lower FiO2 versus a lower end-expiratory lung volume/higher FiO2 ventilation strategy. The ALVEOLI study tested the hypothesis that mortality from ALI and ARDS would be reduced with a mechanical ventilation strategy designed to prevent lung injury from repeated collapse of bronchioles and alveoli at end-expiration.

Background

Most patients requiring mechanical ventilation for ALI and ARDS receive positive end-expiratory pressure (PEEP) of 5 to 12 cm of water. Higher PEEP levels may improve oxygenation and reduce ventilator-induced lung injury but may also cause circulatory depression and lung injury from overdistention. PEEP levels higher than traditional levels may reduce ventilator-induced lung injury by decreasing the proportion of nonaerated lung and higher PEEP levels may allow arterial-oxygenation goals to be met at a lower level of inspired oxygen (FiO2).

Participants

Patients 14 years of age or more, intubated and receiving mechanical ventilation with a sudden decrease in the ratio of the partial pressure of arterial oxygen (PaO2) to FiO2 of 300 or less, recent appearance of bilateral pulmonary infiltrates consistent with the presence of edema, and no evidence of left atrial hypertension. A total of 549 patients were randomized to receive mechanical ventilation with either lower or higher PEEP levels, which were set according to different tables of predetermined combinations of PEEP and fraction of inspired oxygen.

Design

Conclusions

Patients with acute lung injury and ARDS who receive mechanical ventilation with a tidal-volume goal of 6 ml per kilogram of predicted body weight and an end-inspiratory plateau-pressure limit of 30 cm of water, clinical outcomes were statistically similar whether lower or higher PEEP levels are used. (N Engl J Med 2004;351:327-336).

Disease classification

Publications

Mat types

DNA
Plasma

The study population available in BioLINCC study data may be lower than total study enrollment due to Informed Consent restrictions and other factors.

  • Subjects

    Lower PEEP: 274

    Higher PEEP 1, 3: 163

    Higher PEEP 2, 4: 113


    Last Modified: June 22, 2022, 10:05 a.m.
  • Age

     

    Lower PEEP

    Higher PEEP 1,3

    Higher PEEP 2,4

    All

    N

    %

    N

    %

    N

    %

    N

    %

    16-20

    13

    4.74

    2

    1.23

    6

    5.31

    21

    3.82

    21-25

    6

    2.19

    6

    3.68

    3

    2.65

    15

    2.73

    26-30

    20

    7.30

    5

    3.07

    3

    2.65

    28

    5.09

    31-35

    27

    9.85

    7

    4.29

    6

    5.31

    40

    7.27

    36-40

    31

    11.31

    20

    12.27

    10

    8.85

    61

    11.09

    41-45

    33

    12.04

    12

    7.36

    13

    11.50

    58

    10.55

    46-50

    31

    11.31

    17

    10.43

    9

    7.96

    57

    10.36

    51-55

    25

    9.12

    22

    13.50

    11

    9.73

    58

    10.55

    56-60

    12

    4.38

    16

    9.82

    10

    8.85

    38

    6.91

    61-65

    19

    6.93

    13

    7.98

    10

    8.85

    42

    7.64

    66-70

    24

    8.76

    13

    7.98

    5

    4.42

    42

    7.64

    71-75

    13

    4.74

    15

    9.20

    9

    7.96

    37

    6.73

    76-80

    13

    4.74

    8

    4.91

    8

    7.08

    29

    5.27

    81-85

    5

    1.82

    5

    3.07

    6

    5.31

    16

    2.91

    86-90

    2

    0.73

    2

    1.23

    4

    3.54

    8

    1.45

     

    Last Modified: June 22, 2022, 10:05 a.m.
  • Sex
     

     

    Lower PEEP

    Higher PEEP 1,3

    Higher PEEP 2,4

    All

    N

    %

    N

    %

    N

    %

    N

    %

    Female

    145

    52.92

    89

    54.60

    68

    60.18

    302

    54.91

    Male

    129

    47.08

    74

    45.40

    45

    39.82

    248

    45.09

     

    Last Modified: June 22, 2022, 10:05 a.m.
  • Race

     

    Lower PEEP

    Higher PEEP 1,3

    Higher PEEP 2,4

    All

    N

    %

    N

    %

    N

    %

    N

    %

    White non-Hispanic

    201

    73.36

    121

    74.23

    91

    80.53

    413

    75.09

    Black non-Hispanic

    39

    14.23

    25

    15.34

    13

    11.50

    77

    14.00

    Other

    34

    12.41

    17

    10.43

    9

    7.96

    60

    10.91

     

    Last Modified: June 22, 2022, 10:05 a.m.

Please note that biospecimen availability is subject to review by the NHLBI, BioLINCC, and the NHLBI Biorepository. Certain biospecimens may not be made available for your request. Section 3 of the BioLINCC handbook describes the components of the review process

  • Material Types

    Last Modified: Nov. 30, 2015, 1:18 p.m.
  • General Freeze/Thaw Status
  • Visits (Vials)

    06/22/2022

      Plasma Total
    Day 0 3,439 3,439
    Day 1 5,022 5,022
    Day 3 3,054 3,054
    Day 7 3,514 3,514

    Last Modified: June 22, 2022, 10:05 a.m.
  • Visits (Subjects)

    06/22/2022

      Plasma
    Total number of subjects Average volume (ml) per subject
    Day 0 528 6.18
    Day 1 520 12.20
    Day 3 476 8.04
    Day 7 362 12.10

    Last Modified: June 22, 2022, 10:05 a.m.